CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma. Harrison SJ, Touzeau C, Kint N, Li K, et al. N Engl J Med 2025;392:677-685.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Harrison SJ, Touzeau C, Kint N, Li K, et al. CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma. N Engl J Med 2025;392:677-685.
PMID: 39938094